Valeant Pharmaceuticals Intl Inc (VRX) – Statement Regarding the Relative Impact of Restating Earnings – ValueWalk Premium
Valeant VRX new CEO

Valeant Pharmaceuticals Intl Inc (VRX) – Statement Regarding the Relative Impact of Restating Earnings

Valeant Pharmaceuticals Intl Inc (VRX) - Statement Regarding the Relative Impact of Restating Earnings by TheSkeptic

Recent questions have been raised regarding statements made during Valeant Pharmaceuticals Intl Inc’s Third Quarter Investor Presentation, on October 26, 2015, addressing the relative impact of Philidor on Valean'ts growth.  Here are the facts:

  1. On the Investor call, the company provided directional overview of the key elements of the Philidor Program (See Slide #7 of the Investor Presentation, dated October 26, 2015) “Key Elements of the Philidor Program"
  2. SORRY!

    This content is exclusively for paying members.

    If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0